Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

New trial shows major survival gains with epcoritamab added to standard R2 therapy

New trial shows major survival gains with epcoritamab added to standard R2 therapy

Generative AI aids discovery of ISM3830's novel scaffold

Generative AI aids discovery of ISM3830's novel scaffold

A new generation of AML treatments brings hope for better survival

A new generation of AML treatments brings hope for better survival

New consortium aims to fast-track breakthroughs against follicular lymphoma

New consortium aims to fast-track breakthroughs against follicular lymphoma

New medication offers potential treatment for patients with deadliest form of blood cancer

New medication offers potential treatment for patients with deadliest form of blood cancer

New transplant approach resets the immune system to stop Type 1 diabetes

New transplant approach resets the immune system to stop Type 1 diabetes

Novel model expands fertility options for cancer patients

Novel model expands fertility options for cancer patients

Lymphoma resistance mechanisms and future therapies

Lymphoma resistance mechanisms and future therapies

Discovery of 'Mann-type DLBCL' offers hope for more targeted cancer therapies

Discovery of 'Mann-type DLBCL' offers hope for more targeted cancer therapies

Drinking orange juice daily may fine-tune genes tied to cardiovascular wellness

Drinking orange juice daily may fine-tune genes tied to cardiovascular wellness

Common chemical tetrachloroethylene may be harmful to the liver

Common chemical tetrachloroethylene may be harmful to the liver

Rare case of pancreatic Hodgkin lymphoma is often misdiagnosed as pancreatic adenocarcinoma

Rare case of pancreatic Hodgkin lymphoma is often misdiagnosed as pancreatic adenocarcinoma

Epigenetic editing enables safer and more effective T cell therapies

Epigenetic editing enables safer and more effective T cell therapies

What happens when microplastics reach the testes? Study shows autophagy and cell loss

What happens when microplastics reach the testes? Study shows autophagy and cell loss

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Age alone may not predict outcomes in acute myeloid leukemia

Age alone may not predict outcomes in acute myeloid leukemia

New GoT-Multi technology reveals how cancers evolve and resist treatment

New GoT-Multi technology reveals how cancers evolve and resist treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.